Introduction: Appropriate titration of basal insulin (BI) is essential to achieve glycemic control in patients with type 2 diabetes (T2D) . However, optimal glucose control is often unattained due to challenges with BI titration. This survey study reports physician experiences with BI titration.

Methods: Physicians in the Optum Research Database who treated ≥30 patients with T2D, with ≥1 who initiated BI from 10/01/20 to 03/31/21, were asked to complete a one-time mailed survey.

Results: Among 386 responders, 70% were male, 76% in general practice, 63% had ≥20-years’ experience, and 29% practiced in rural regions. Most (90%) physicians reported seeing >50 patients with T2D in the prior 6 months, and 66% treated ≥25% of them with BI. The majority (77%) expected glucose control attainment within 12 weeks, and 51% estimated <25% of patients were unable to reach HbA1c goal. Most (86%) physicians explained titration to all/most of their patients new to BI. Only 27% expected patients to self-manage titration; 60% managed titration for them, and 13% did both. Most (84%) physicians had in-office titration education by healthcare providers, 42% provided ongoing access to them; only 13% provided digital tools. The majority expressed concerns about patients’ abilities to follow titration algorithms (79%) , and to monitor blood glucose effectively (66%) , as well as lack of engagement in the titration process (72%) .

Conclusion: Physicians reported counseling most new-to-BI patients for titration and providing ongoing clinical guidance and non-digital support tools. Despite this, the majority of physicians expressed concern about patients' abilities to manage self-titration effectively. These findings support the need for novel approaches or tools to support patients during BI titration.

Disclosure

S.B.Harris: Consultant; Abbott, AstraZeneca, Eli Lilly and Company, Novo Nordisk, Sanofi, Other Relationship; Abbott, AstraZeneca, Bayer Inc., Dexcom, Eli Lilly and Company, HLS Therapeutics, Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi, Research Support; Applied Therapeutics Inc., AstraZeneca, Canadian Institutes of Health Research, Juvenile Diabetes Research Foundation (JDRF) , Novo Nordisk, Sanofi, The Lawson Foundation. J.Seufert: Advisory Panel; Abbott, Sanofi-Aventis Deutschland GmbH, Research Support; Boehringer Ingelheim International GmbH, Speaker's Bureau; Abbott Diabetes, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Lilly, Novo Nordisk, Sanofi-Aventis Deutschland GmbH. M.Bertolini: Employee; Sanofi. V.Walker: Consultant; Sanofi-Aventis U.S. J.C.White: Consultant; Sanofi-Aventis U.S. F.L.Zhou: Employee; Sanofi, Stock/Shareholder; Sanofi. K.Mohammedi: Board Member; Lilly, Novo Nordisk, Sanofi, Research Support; Cyclerion Therapeutics, Inc., Speaker's Bureau; Abbott, AstraZeneca. J.E.Anderson: Advisory Panel; Abbott Diabetes, Consultant; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Gelesis, Novo Nordisk, Sanofi, Speaker's Bureau; Eli Lilly and Company.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.